Why Is ImmunityBio (IBRX) Stock Up Premarket? ANKTIVA Sales Jump 700%

ImmunityBio, Inc. (NASDAQ: IBRX) shares surged dramatically in recent trading sessions following the company’s announcement of exceptional preliminary financial results for fiscal year 2025. The commercial-stage biotechnology company reported approximately $113 million in preliminary net product revenue, representing a remarkable 700% year-over-year increase driven primarily by accelerating adoption of its flagship immunotherapy drug ANKTIVA.

The strong revenue performance, combined with significant regulatory approvals in international markets and robust quarter-over-quarter growth momentum, has ignited investor enthusiasm and positioned ImmunityBio as one of the notable success stories in the biotechnology sector entering 2026.

Record Revenue Growth as ANKTIVA Sales Accelerate

ImmunityBio delivered extraordinary financial results for 2025, reporting preliminary net product revenue of approximately $113 million for the full year, reflecting a remarkable 700% increase compared to 2024. The company’s flagship product ANKTIVA, the first FDA-approved immunotherapy for non-muscle invasive bladder cancer carcinoma in situ, demonstrated exceptional market adoption with unit sales volume growing 750% year-over-year.

Fourth quarter 2025 revenue reached approximately $38.3 million, surpassing the third quarter’s $31.8 million and marking a 20% sequential increase and 431% year-over-year jump. President and CEO Richard Adcock attributed the success to accelerating adoption of ANKTIVA and continued execution of the company’s commercial strategy, with the company maintaining a 54% quarter-over-quarter unit volume growth rate throughout fiscal 2025.

Join our Telegram group and never miss a breaking digital asset story.

IBRX Stock Brief: Premarket Trading and Market Performance

As of early morning January 16, 2026, ImmunityBio stock was trading at approximately $3.15 in premarket activity, down slightly from the previous session’s dramatic gains. The stock had closed at $3.02 on Wednesday before surging more than 28% on Thursday, January 15, reaching highs near $3.99 during intraday trading and settling around $3.91-$3.95.

This represented one of the strongest single-day performances for IBRX in recent months, with trading volume reaching 58.75 million shares compared to the average daily volume of 16.44 million shares. Over the past 52 weeks, the stock has traded in a range between $1.83 and $4.27, with the recent surge pushing shares closer to the upper end of that range.

Analyst consensus remains bullish on the stock, with five analysts recommending buying and an average 12-month price target of $10.40, representing potential upside of over 200% from current levels. The highest analyst target stands at $24.00 from D. Boral Capital, reflecting strong confidence in the company’s commercial trajectory.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.